Hepatic artery chronomodulated infusion of irinotecan, 5-fluorouracil and oxaliplatin against liver metastases in heavily pretreated patients with colorectal cancer.

被引：0
|
作者：
Bouchahda, M
Tanaka, K
Adam, R
Giacchetti, S
Brézault-Bonnet, C
Gholam, D
Kunslinger, F
Castaing, D
Jasmin, C
Lévi, FA
机构：
[1] Hop Paul Brousse, Villejuif, France
[2] INSERM, E0354, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3722
引用
收藏
页码：299S / 299S
页数：1
相关论文
共 50 条
  • [41] Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver
    van Riel, JMGH
    van Groeningen, CJ
    de Greve, J
    Gruia, G
    Pinedo, HM
    Giaccone, G
    ANNALS OF ONCOLOGY, 2004, 15 (01) : 59 - 63
  • [42] Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma -: A phase I study
    Garufi, G
    Dogliotti, L
    D'Attino, RM
    Tampellini, M
    Aschelter, AM
    Pugliese, P
    Perrone, M
    Nisticó, C
    Comis, S
    Terzoli, E
    CANCER, 2001, 91 (04) : 712 - 720
  • [43] Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC)
    Kouroussis, C
    Souglakos, J
    Mavroudis, D
    Papadouris, S
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Panopoulos, C
    Vardakis, N
    Sarra, E
    Georgoulias, V
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06): : 627 - 631
  • [44] Hepatic artery infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastasis from colorectal cancer. Final analysis of a phase I/II studay.
    Moosmann, L
    Kern, W
    Waggershauser, T
    Hiddemann, W
    Heinemann, V
    Schalhorn, A
    Grosshadern, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 278S - 278S
  • [45] CONTINUOUS HEPATIC-ARTERY INFUSION OF 5-FLUOROURACIL FOR METASTATIC COLORECTAL-CANCER LOCALIZED TO THE LIVER
    BOYLE, FM
    SMITH, RC
    LEVI, JA
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1993, 23 (01): : 32 - 34
  • [46] Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer
    Hosokawa, A
    Yamada, Y
    Shimada, Y
    Muro, K
    Matsumura, Y
    Fujita, S
    Akasu, T
    Moriya, Y
    Shirao, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (03) : 132 - 135
  • [47] A phase I study of hepatic arterial infusion (HAI) of irinotecan in patients with inoperable liver metastases of colorectal cancer.
    Vogl, TJ
    Eichler, K
    Mack, MG
    Balzer, JO
    Herzog, C
    Söllner, O
    Zangos, S
    Thalhammer, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 297S - 297S
  • [48] Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer
    Del Freo, Alfonso
    Fiorentini, Giammaria
    Sanguinetti, Franco
    Muttini, Maria Pia
    Pennucci, Cristina
    Mambrini, Andrea
    Pacetti, Paola
    Della Seta, Roberta
    Lombardi, Mirko
    Torri, Tito
    Cantore, Maurizio
    IN VIVO, 2006, 20 (6A): : 743 - 746
  • [49] SAFETY AND EFFICACY OF INTRAVENOUS CETUXIMAB (CET) AND HEPATIC ARTERY INFUSION OF IRINOTECAN, 5-FLUOROURACIL AND OXALIPLATIN IN PATIENTS WITH UNRESECTABLE LIVER METASTASES FROM WT KRAS COLORECTAL CANCER (CRC): RESULTS FROM OPTILIV EUROPEAN PHASE II TRIAL
    Levi, F.
    Boige, V.
    Rougier, P.
    Hebbar, M.
    Smith, D.
    Focan, C.
    Guimbaud, R.
    Carvalho, C.
    Bouchahda, M.
    Ducreux, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 194 - 194
  • [50] Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer -: A feasibility pilot study
    Calvo, E
    Cortés, J
    González-Cao, M
    Rodríguez, J
    Aramendía, JM
    Fernández-Hidalgo, O
    Martín-Algarra, S
    Salgado, JE
    Martínez-Monge, R
    de Irala, J
    Brugarolas, A
    ONCOLOGY, 2002, 63 (03) : 254 - 265
12345